Nerai Bio is focused on advancing genetic medicine through innovative approaches in protein engineering and artificial intelligence (AI). The company aims to leverage these technologies to develop novel therapeutic solutions that can address complex medical challenges. By integrating AI with protein engineering, Nerai Bio seeks to enhance the design and optimization of proteins, potentially leading to more effective treatments and improved patient outcomes.

The company's pipeline includes a range of products that are under development, showcasing their commitment to pushing the boundaries of genetic medicine. Through their scientific expertise and technological advancements, Nerai Bio is positioned to make significant contributions to the field, aiming to transform how genetic disorders are treated and managed. Their work reflects a dedication to harnessing cutting-edge science to create impactful healthcare solutions.

Switzerland

Nerai Bio is a biotech startup pioneering ultra-specific genome editing technologies to treat genetic diseases. Using their AI-driven MORPHEME platform, they engineer novel gene-editing proteins that can precisely target and correct DNA at any location, addressing a broader range of genetic mutations than existing tools like CRISPR. Their lead therapeutic candidates focus on severe liver disorders, aiming to provide a single, permanent cure for conditions currently treated with lifelong care. Recently, Nerai Bio secured CHF 150,000 from Venture Kick to advance business development, preclinical validation studies, and partnerships.

Nerai Bio

Company Details